Fighting infectious diseases with immunotherapy on ‘cusp of commercialization’

allergies

Immunotherapy, which involves adapting immune cells to destroy specific cellular targets, has made a name for itself treating cancer. But over the last few years, a handful of research groups have advanced T-cell therapies for viral infections, and are now on the cusp of commercialization. “Using T cells to target infectious diseases is not a new field,” says immunologist Michael Keller of Children’s National Hospital in Washington, D.C., “but it’s something that’s expanding a great deal.”

…

So researchers are pursuing a combination of strategies aimed at either banking T cells from donors who have already experienced viral infections or training virus-naive T cells taken from unexposed tissues such as umbilical cord blood to help make antiviral immunotherapies more robust and more widely available.

…

Over the past several decades, most research on antiviral T cells has focused on people undergoing bone marrow transplants for blood cancers such as leukemia.

…

Pharmaceutical firms have invested billions of dollars in cancer immunotherapies over the last few years, and the US Food and Drug Administration (FDA) began approving such therapies in recent months. But the investment bonanza has yet to hit antiviral T-cell therapy. While a handful of companies, including Atara, Viracyte, Tessa, and Cell Medica, have partnered with university researchers and conducted Phase 2 trials, most of the work on antiviral T-cell therapy is still funded by governments and private philanthropy, Keller says.

Read full, original post: Antiviral Immunotherapy Comes of Age

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-11-16-at-2.37.32-PM
30 years of GMO farming: Is the boom in glyphosate and glufosinate use harming the environment? Data show they’re the most sustainable choice
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Stormlit Portrait Over Golden Mountains
Searching for life where no one thought to look: A renowned astrophysicist’s seemingly quixotic quest to explore Venus’s clouds
Screenshot-2026-11-19-at-7.23.23-PM
Viewpoint: After a yearlong hiatus, the U.S. Preventive Services Task Force is back in business—gutted by RFK Jr. and promoting junk science
Soybean Harvest in Cupped Hands
30 years of GMO farming: Defying cynics, we’ve had larger harvests, lower costs, and $385 billion in added global farmer income
Screenshot-2026-11-17-at-12.18.09-PM
Challenging glyphosate fear-mongering: Statewide Nebraska study finds no link between weedkiller use and non-Hodgkin lymphoma
Screenshot-2026-11-19-at-7.54.57-PM
European General Court sides with scientists, dismisses activist claims that glyphosate is toxically dangerous
Nurturing Care Beneath the Crunchy Moms Logo
Crunchy Moms disinformation flood: Zuckerberg's Facebook has opened floodgates on measles and vaccines
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.